Straits Times Index
3,270.98 -11.90 (-0.36%) S&P 500
4,174.53 +29.34 (+0.71%) Dow
33,044.99 +241.52 (+0.74%) Nasdaq
12,784.46 +126.91 (+1.00%) BTC-USD
24,167.51 +1,041.38 (+4.50%) CMC Crypto 200
564.56 +21.68 (+3.99%)
Gilead Sciences, Inc. (GILD)
| Previous close | 61.09 |
| Open | 61.00 |
| Bid | 61.46 x 1400 |
| Ask | 61.46 x 1000 |
| Day's range | 60.82 - 61.61 |
| 52-week range | 57.17 - 74.12 |
| Volume | |
| Avg. volume | 7,223,551 |
| Market cap | 77.178B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 18.82 |
| EPS (TTM) | 3.27 |
| Earnings date | 26 Oct 2022 - 31 Oct 2022 |
| Forward dividend & yield | 2.92 (4.78%) |
| Ex-dividend date | 14 Sept 2022 |
| 1y target est | 69.96 |
- Motley Fool
2 Reasons This Beaten-Down Stock Could Be About to Rebound
Gilead Sciences (NASDAQ: GILD) has kept its revenue and earnings growing in the past two years -- if ever so slightly -- largely thanks to Veklury, its COVID-19 therapy. Gilead Sciences' revenue rose by only about 1% year over year to $6.3 billion during the period. Excluding sales of Veklury, which dropped by 46% year over year to $445 million, Gilead Sciences' revenue for the quarter grew by a more impressive and respectable (by industry standards) 7%.
- Business Wire
Gilead Sciences to Acquire MiroBio
FOSTER CITY, Calif. & OXFORD, England, August 04, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors, today announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in cash, subject to customary adjustments.
